Background: To analyze the pregnancy complications and pregnancy outcome relating to the disease activity of systemic lupus erythematosus before conception and during pregnancy. Methods: Seventy-two pregnancies were collected in a single tertiary medical center within a 5-year period. Twelve pregnancies were terminated due to various causes in the first half of pregnancy. Analysis of pregnancy complications and pregnancy outcome relating to the lupus activity before conception and during pregnancy was made among the remaining 60 pregnancies with gestational length > 26 weeks. The assessment of lupus activity was based on the routine monitoring, including urine routine, white blood cell count, hemoglobin and platelet count, erythrocyte sediment rate, serum titers of C 3 , C 4 , and double-stranded DNA. Monitoring of renal function with daily urinary protein loss and clearance rate of creatinine was needed when worsened nephropathy was suspected. Results: The etiologies of the terminated pregnancies were deteriorated nephropathy (6 cases), involvement of central nervous system (1 case), unwanted pregnancy due to drug exposure (3 cases), and two early intrauterine fetal deaths (both during the 23 rd week of gestation). Pregnancy complications were related to the lupus activity before conception [odds ratio ¼ 0.238, 95% confidence interval (CI) ¼ 0.073, 0.778, p ¼ 0.014] and during pregnancy (odds ratio ¼ 0.153, 95% CI ¼ 0.031, 0.754, p ¼ 0.012). Meanwhile, pregnancy outcome significantly related to the lupus activity of the preconception period and during pregnancy. The gestational length was significantly longer in the pregnancies with remitted lupus activity either before conception (38.2 ± 1.6 weeks vs. 36.3 ± 3.4 weeks, p ¼ 0.011 and 95% CI ¼ À3.454, À0.478) or during pregnancy (38.2 ± 1.6 weeks vs. 35.2 ± 3.8 weeks, p ¼ 0.005 and with 95% CI ¼ À4.988, À1.005). Significant relationships were also found between newborn birth weights and lupus activity preconceptionally (2940 ± 389 g vs. 2448 ± 674 g, p ¼ 0.002 and 95% CI ¼ À792, À192) and after having conceived (2960 ± 383 g vs. 2136 ± 585 g, p < 0.001 and 95% CI ¼ À1081, À568). Multivariate analysis showed that lupus remission during pregnancy was correlated with a significantly longer gestation, since pregnant women with active lupus had a three-fold greater risk of preterm deliveries (hazard ratio ¼ 3.022, 95% CI ¼ 1.261, 7.242) compared with pregnant women without active lupus. Conclusion: In order to reduce the incidence of pregnancy complication, especially preterm delivery, and to gain good pregnancy outcome, good preparation before conception and good control of the disease during pregnancy are mandatory.
Introduction
Systemic lupus erythematosus (SLE) is the most common immunologic disorder in women of reproductive age. It produces specific symptoms and signs of involved organs. Fertility is not affected when the disease activity is controlled. 1 Stable preconceptional lupus activity is recommended for planning pregnancy. 2 However, some patients become pregnant unexpectedly without remission. Termination of pregnancy may not be needed if there were neither severe lupus nephropathy nor involvement of central nervous system at the time of conception.
Many complications, such as abortion, fetal loss, preterm birth, pregnancy-induced hypertension, preeclampsia superimposed on chronic hypertension, intrauterine fetal distress, and fetal growth restriction make pregnancies with lupus very complicated, especially in those cases who were not well prepared for conception. 3e5 However, the correlation between pregnancy outcome and preconceptional lupus activity was still questionable for lack of convincing analysis. In this study, statistical analyses of the pregnancy complications and pregnancy outcomes associated with the lupus activity before conception and during pregnancy was done only on those cases that gave birth after completing 26 weeks of gestation.
Methods
From July 2008 to June 2013, all pregnant women suffering from SLE who gave birth to their babies in a single tertiary center hospital (Taipei Veterans General Hospital, Taipei, Taiwan) were enrolled in this study. With permits of the patients, the following data were collected: age, gravidity, parity, age at the onset of disease, duration of disease, lupus activity before and after conception, complications during pregnancy, newborn birth weight, gestational age at delivery, and medications given before conception and during pregnancy. All the women enrolled were followed-up regularly at the prenatal clinic and at least once per month by a rheumatologist. Intensive care was given when the disease activity was relapsing (flare-up) or becoming worse.
Other than clinical symptoms, the assessment of the lupus activity was based on the routine monitors, including urinalysis, white blood cell count, hemoglobin level, platelet count, erythrocyte sediment rate, and serum levels of C 3 , C 4 , and double-stranded DNA. Monitoring renal function with daily urinary protein loss and measurement of creatinine clearance as well as serum blood urea nitrogen and creatinine were needed, especially when exacerbated nephropathy was suspected. If the above measurements were all within normal limits, the patient's lupus activity was defined as "stable" or "in remission". Lupus activity was defined as "relapsed" or "without remission" when some or all of the above measurements went out of normal limits in those cases who were originally with remission. It was defined as "deteriorated" or "exacerbated" when some or all of the above measurements were worsening in those cases that were originally not remitted.
Pregnancy complications included threatened abortion, preterm labor, preterm delivery, gestational diabetes mellitus (GDM), pregnancy-induced hypertension, preeclampsia, chronic hypertension, intrauterine chronic fetal distress, intrauterine growth restriction (IUGR), and perinatal loss (including intrauterine fetal death and neonatal loss).
The data were analyzed with independent-sample t test between continuous variables, and with c 2 test between noncontinuous variables. Survival (preterm delivery, defined as delivery occurring at < 37 weeks of gestation) was determined on the basis of parameters and patient outcomes. Estimates of the proportion of overall survival (OS) were calculated by the KaplaneMeier procedure, and differences in survival were evaluated via log-rank test. Covariance analysis and the hierarchic c 2 test were used to control for potential confounding factors in the comparison of patients' characteristics and risk factors. The log-rank test, hazard ratio (HR), and 95% confidence interval (CI) of preterm births from pregnant women with SLE were calculated via Cox proportional hazards model with univariate and multivariate analysis of OS. SPSS version 20 (SPSS Inc., Chicago, IL, USA) was used for statistical analysis. Statistical significance was determined by unpaired two-tailed Student t test using a pooled estimator of variance, and was defined as p < 0.05. The study project was approved by the Institutional Review Board of Taipei Veterans General Hospital (IRB No. 2011-12-0171B#1).
Results
Sixty-five women with SLE had 72 pregnancies during the study period from July 2008 to June 2013. Twelve pregnancies in 12 patients were excluded due to termination for various causes in the first half of pregnancy. Six of them were terminated due to deteriorated lupus nephropathy. One of these six patients died thereafter due to poor response to immunosuppressive treatment. Of the remaining six pregnancies, one was terminated due to the involvement of the central nervous system by SLE; three were terminated because of drug exposure; and the remaining two were terminated due to intrauterine fetal death. One fetal death resulted from twisted cord found during the 23 rd week of gestation, and the other one was the consequence of deteriorated nephropathy during the 23 rd week of gestation. The remaining 60 pregnancies in 55 women who gave birth to their newborns after 26 completed weeks' gestation were divided into two groups based on the preconceptional lupus activity, with remission and without remission. There were 34 (56.7%) cases with remission, and the remaining 26 (43.3%) cases were not remitted preconceptionally. The same work was done on the base of lupus activity during pregnancy. At delivery, the remission group had 43 cases and the remaining 17 cases were without remission. The total number of deliveries during the same period of time was 9419. The incidence of delivery with SLE was 0.64% (60/9419).
Mean age of the patients of the 60 pregnancies was 29.7 ± 4.8 years old, with range between 20 years and 43 years. Mean gravidity was 2.6 ± 1.4, range 1e6. The average parity was 1.7 ± 0.8, range 1e3. Sixty-one (1 set of twins) babies were born, with one intrauterine fetal death at 35 weeks' gestation. The mean birth weight of newborns was 2727 ± 581 g, range 890e3885 g. The mean gestational age of birth was 37.4 ± 2.6 weeks, range 26e41 weeks. The mean age of onset of SLE was 24.2 ± 5.6 years, range 12e37 years. The mean duration of the disease was 5.4 ± 3.7 years, range < 1e17 years (Table 1) .
Lupus activity during pregnancy
Four of the 34 originally preconceptional remission cases relapsed during pregnancy. Three of them were diagnosed during the first trimester, the remaining one relapsed during the third trimester. In the first trimester, one of them went into remission again after adjuvant plaquenil was given. Two of the 26 originally preconceptional without remission cases went into remission during pregnancy without changing treatment regimens. Ten of the remaining 24 pregnancies went into remission after treatment regimens were changed. Of the relapsed or deteriorated cases, 17 pregnancies were found during the first trimester, eight in the second trimester, and two in the third trimester. Consequently, there were 43 pregnancies having remission of lupus activity at delivery, and 17 without remission.
Lupus activity and pregnancy complications
In the preconceptional remission group (n ¼ 34), four cases (11.8%) suffered from preterm birth. Pregnancy-induced hypertension was found in six (17.6%) cases. Three (8.8%) cases experienced threatened abortion. Placental abruption was found in one pregnancy. Gestational diabetes mellitus was disclosed in three (8.8%) cases. Seventeen (50%) pregnancies were free from complications. By contrast, in the group of pregnancies without remission preconceptionally (n ¼ 26), only five (19.2%) pregnancies were free from complications during gestational periods. Six (23.1%) patients suffered from pregnancy-induced hypertension. Threatened abortion was found in six (23.1%) cases. Nine (34.6%) pregnancies ended in preterm birth, four (15.4%) were with IUGR, three (11.5%) were with renal failure, three (11.5%) were with chronic hypertension, one (3.8%) was with intrauterine fetal distress, two (7.7%) were with placental abruption, and one (3.8%) was with intrauterine fetal loss. Significant correlations were found between preconceptional lupus activity and pregnancy complications. Table 2 ).
In the group of stable lupus activity during pregnancy (n ¼ 43), 20 (46.5%) pregnancies were free from complications. Eight (18.6%) cases experienced threatened abortion. Preterm birth was found in five (11.6%) patients, three (7.0%) patients were with GDM, pregnancy-induced hypertension in seven (16.3%), two (4.7%) suffering from placental abruption, and one (2.3%) was with IUGR. In the group of unstable lupus activity (n ¼ 17), only two (11.8%) cases were free from pregnancy complications. Intrauterine fetal death occurred in one (5.9%) case, one (5.9%) was with threatened abortion, eight (47.1%) were with preterm birth, five (29.4%) were with pregnancy-induced hypertension, three (17.6%) were with IUGR, three (17.6%) were with renal failure, three (17.6%) were with chronic hypertension, placental abruption in one pregnancy (5.9%), and one (5.9%) was with intrauterine fetal distress. Lupus activity was correlated to preterm birth Table 2 ).
Pregnancy outcomes
Both newborn birth weight and gestational length were related to preconceptional lupus activity. The mean birth weights of the preconceptional remission group and no remission group were 2940 ± 389 g (range, 2060e3885 g) and 2448 ± 674 g (range, 890e3524 g), respectively. Significant correlation was found by t test analysis, with p ¼ 0.002 and 95% CI ¼ À792, À192. The mean gestational ages of the two groups were 38.4 ± 1.6 weeks (range, 34e41 weeks) and 36.3 ± 3.4 weeks (range, 26e41 weeks), respectively. Analysis with t test showed significant correlation with p ¼ 0.011 and 95% CI ¼ À3.454, À0.478 (Table 3) .
Similarly, both newborn birth weight and gestational length were significantly correlated to lupus activity during pregnancy. The mean birth weight of the remission group was 2960 ± 383 g, range 2060e3885 g. In the lupus activity group without remission, the mean birth weight was 2136 ± 585 g, range 890e2760 g. By analysis with t test, there was significant correlation, with p < 0.001 and 95% CI ¼ À1081, À568. In the group with remission, mean gestational age was 38.2 ± 1.6 weeks, range 34e41 weeks. The mean gestational age of the group without remission was 35.2 ± 3.8 weeks, range 26e40 weeks. There was significant correlation, with p ¼ 0.005 and 95% CI ¼ À4.988, À1.005, analyzed with t test (Table 4) . 
The risk of preterm delivery (<37 weeks of gestation)
Since preterm delivery might be the most important single factor to predict fetal outcome, we used 37 gestational weeks as a cutoff value to investigate the risk factors in women with SLE. Univariate analysis showed that only remission of SLE during pregnancy was significant, since the women without remission of SLE during pregnancy had a higher risk of preterm delivery (HR ¼ 2.335, 95% CI ¼ 1.124, 4.847). Furthermore, multivariate analysis confirmed that remission of SLE during pregnancy was the single most important predictor of preterm delivery. Women without remission of SLE during pregnancy had a three-fold risk of preterm deliveries (<37 weeks of gestation) compared to those women with remission (HR ¼ 3.022, 95% CI ¼ 1.261, 7.242; Table 5 ).
Discussion
Flaring up of lupus during pregnancy is common and occurs significantly more frequently than does flare up in nonpregnant SLE patients or in the same patients after pregnancy. 6 Therefore, in order to reduce the frequency of lupus flare-up during pregnancy and to get good pregnancy outcome, remission of SLE for 6 months before conception was recommended for planned pregnancy. 7 However, fertility was usually not affected unless the patient was critically ill with SLE. Some of the patients conceived without planning or good control of the disease. Consequently, obstetric complications and poor pregnancy outcomes were commonly seen in those cases with active lupus activity during pregnancies.
Flare-up of lupus activity was found mostly during the second trimester and the postpartum period. 8 It was supposed that medication was discontinued during the first trimester and resulted in the flare-up during the second trimester. However, lupus flare-up could happen in all three trimesters, 9 although low probability in the third trimester due to a lower humoral immune response resulted from the lack of estrogen increment was found. 10 In our study, flare-ups were mostly found during the first trimester, especially in those cases of the preconceptional nonremission group, and lowest during the third trimester. Cessation or reduction of medication during the first trimester due to gastrointestinal disturbance, rejection or reluctance to take medicines to avoid fetal injury might be the most probable factors of flare-up. In this study, medication was adjusted as soon as possible whenever relapsed or deteriorated lupus activity was found. A large portion of these flare-up patients experienced remission after treatment regimen was revised, and consequently, significant good pregnancy outcomes were obtained, which was not the same as the findings of Petri et al. 6 Other than nephropathy with heavy protein loss or low clearance rate of creatinine, in patients complicated with preeclampsia, the assessment of severity was based upon the changes of the following, including platelet count, liver, renal functions, coagulation tests (activated partial thromboplastin time, prothrombin time, fibrinogen, fibrin degradation products, protamine sulfate test), fetal growth rate, uteroplacental function test, blood pressure, daily urinary output, signs of central nervous system, respiration distress (sign of severe edema), etc. As soon as there was an abnormal finding, the patient was classified as severe type, and termination of pregnancy was indicated to save the fetus and the parturient. Similarly, when pregnancy was complicated with SLE, in addition to nephropathy, the obstetrician had to take great care regarding the status of lupus activity in order to modify the treatment regimen in those cases with flare-up, relapse, or deterioration. The lupus activity index, the University of Toronto SLE disease activity index score, and the physician's global assessment were at the time used for monitoring lupus activity during pregnancy. However, they were complicated to use. Also, there was not enough time to adjust the treatment regimen if lupus activity had relapsed or deteriorated, especially in the second half of pregnancy. Therefore, in this study, we simplified the manner of assessing lupus activity during pregnancy to be just like that for preeclampsia. If there were abnormal findings, including blood tests, symptoms, and signs, flare-up or deterioration should be considered and modification of the treatment regimen had to be done as soon as possible. With a simple assessment method for lupus activity and quick modification of treatment regimen, better pregnancy outcomes were achieved in this study.
Issues concerning the dosage of medications needed during pregnancy have been raised. Azathioprine (imuran) and chloroquine had been regarded as teratogens to the fetus, resulting in their discontinued use during pregnancy, at least during the first trimester. However, the safety of using imuran and hydroxychloroquine (plaquenil) during pregnancies is well documented.
11e14 Therefore, not only the usage but also the dosage of these immunosuppressive agents needed to be maintained, even though the lupus activity was in remission during pregnancy. By contrast, increase of the dosage or adjuvant therapy was required if there was lupus relapse or exacerbation during pregnancy.
There were four cases of SLE with first onset during pregnancy found in this study, and they were classified as a preconceptional unstable group with deterioration of lupus activity during pregnancy. Except for one case that was found during the first trimester, the other three pregnancies were first complicated with SLE during the second trimester. In addition to steroids, immunosuppressive agents, such as imuran and plaquenil, were used as soon as the diagnosis of SLE had been given. Although two of the patients suffered from preeclampsia, all four pregnancies resulted in favorable outcomes after the lupus was under good control. 15 Based on the experiences with these four cases, we found that the first onset of lupus during pregnancy was not a disaster. Good pregnancy outcome could be achieved after good medical care was provided. In addition, unless there was a specific indication, such as acute pulmonary edema due to heart failure, or renal failure, termination of pregnancy was not necessary. Pregnancy complications such as abortion, preterm labor, and birth, 16 intrauterine fetal death, preeclampsia, eclampsia, and intrauterine fetal growth restriction, are commonly seen in pregnancies complicated with SLE. Preterm birth (gestational age <37 weeks) had been found to be associated with the disease activity by Clark et al. 16 In this study, we also noted the importance of lupus activity associated with the length of gestation either preconceptionally or during pregnancy. In addition, significant differences were found in newborn weight, related either to the preconceptional lupus activity (t test, 2940 g vs. 2448 g, p ¼ 0.002, 95% CI ¼ À792, À192) or to the disease activity during pregnancy (t test, 2978 g vs. 2142 g, p < 0.001, 95% CI ¼ À1137, À536). High incidence of pregnancy-induced hypertension (12/60, 20%) was found in this series, but there was no significant difference associated with the disease activity. However, the number of pregnancies free from complications (22/60, 36.7%), was significantly greater in the group with remission of lupus activity than in that without remission, either preconceptionally (17/34 vs. In addition, preterm birth, chronic hypertension, IUGR, and renal failure were also correlated to the lupus activity either preconceptionally or during pregnancy.
The use of steroids during pregnancy had been regarded as the etiology of gestational diabetes mellitus. There were only three cases that suffered from GDM in this series. The number was too small to evaluate the interrelationships. The dosage and the duration of steroids used might be related to this gestational complication. However, a larger series is needed to draw a conclusion.
In conclusion, women suffering from SLE are no longer contraindicated for pregnancy unless they have not achieved a good control of lupus activity or have poor renal function. With adjuvant therapy with azathioprine and hydroxychloroquine, the lowest effective dose of steroids is advocated for good preconceptional control to avoid pregnancy complications. In addition, maintenance of treatment regimen and close followup with stringent monitoring of the lupus activity prenatally are the only ways to gain favorable pregnancy outcome.
